Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
Federal and state regulators are moving to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. The Federal Trade Commission and seven states claim Shkreli breached the restriction by trading drug stocks and providing market commentary that influenced biopharma equities. Regulators are asking a judge to find him in contempt and are demanding that he divest his pharmaceutical holdings. The fresh legal action places the controversial executive back in the sights of authorities following previous federal enforcement actions.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The Federal Trade Commission and seven states filed a contempt claim against Martin Shkreli.
- ✓ Regulators accuse Shkreli of violating a lifetime pharmaceutical industry ban.
- ✓ The FTC demands that Martin Shkreli divest his pharmaceutical stocks.
What changed
The Federal Trade Commission and seven states filed a contempt claim against Martin Shkreli for trading drug stocks and issuing market commentary.
Live updates
-
FTC and States Accuse Martin Shkreli of Violating Pharma Ban
Federal and state regulators are moving to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. The Federal Trade Commission and seven states claim Shkreli breached the restriction by trading drug stocks and providing market commentary that influenced biopharma equities. Regulators are asking a judge to find him in contempt and are demanding that he divest his pharmaceutical holdings. The fresh legal action places the controversial executive back in the sights of authorities following previous federal enforcement actions.
Why it matters
The contempt action stems from prior legal penalties that barred Shkreli from participating in the pharmaceutical industry for life. Regulators monitor such bans to prevent individuals found liable for anticompetitive conduct or market manipulation from re-exercising influence over drug companies and sector stocks. The current motion tests the enforcement limits of judicial bans when applied to stock trading and public commentary.
What is confirmed
- The Federal Trade Commission and seven states filed a contempt claim against Martin Shkreli.
- Regulators accuse Shkreli of violating a lifetime pharmaceutical industry ban.
- The FTC demands that Martin Shkreli divest his pharmaceutical stocks.
What to watch next
- A judicial decision on the contempt motion
- Court orders regarding the demand for Shkreli to divest his pharma stocks
confidence 100%Sources used for this update (15)
- CNBC — Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim
- Bloomberg.com — Shkreli Faces Contempt for Breaking Pharmaceutical Industry Ban
- MarketWatch — ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
- upi — FTC asks judge to find 'Pharma Bro' Martin Shkreli in contempt
- STAT — FTC demands Martin Shkreli divest his pharma stocks
- Investing.com — FTC targets Martin Shkreli over pharma stock trading and market commentary
- The Guardian — FTC and seven states seek contempt ruling against Shkreli over pharma ban
- WSJ — FTC, States Ask Court to Hold ‘Pharma Bro’ Shkreli in Contempt for Trading Drug Stocks
- CNN — ‘Pharma Bro’ Martin Shkreli has caught the attention of federal and state authorities again
- The New York Times — Martin Shkreli Violated Lifetime Ban From Drug Industry, U.S. Says
- github.com — GitHub - torvalds/linux: Linux kernel source tree · GitHub
- en.wikipedia.org — Linux kernel - Wikipedia
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community